CompanyCTNMNasdaqSan Diego, CA

Contineum Therapeutics

Contineum Therapeutics develops oral small molecule therapies for inflammatory and fibrotic diseases.

SEC EDGAR ClinicalTrials.gov contineum-tx.com

8-KSep 14Latest SEC filing, period to Sep 14

Sep 14Latest story

September 2026

Contineum's MOONLIGHT-1 Phase 2 trial fails to hit primary endpoint in depression

Sep 14Clinical readoutContineum Therapeutics

July 2026

Contineum reports Q2 2026 results, affirms IPF and MDD trial timelines

Jul 30Quarterly updateContineum Therapeutics